JP2011520456A - 抗癌療法に対する応答を予測するための組み合わせ方法 - Google Patents

抗癌療法に対する応答を予測するための組み合わせ方法 Download PDF

Info

Publication number
JP2011520456A
JP2011520456A JP2011509855A JP2011509855A JP2011520456A JP 2011520456 A JP2011520456 A JP 2011520456A JP 2011509855 A JP2011509855 A JP 2011509855A JP 2011509855 A JP2011509855 A JP 2011509855A JP 2011520456 A JP2011520456 A JP 2011520456A
Authority
JP
Japan
Prior art keywords
timp
dna
top2a
her2
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011509855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520456A5 (https=
Inventor
アージェ ブルンナー，ニルス
バング ニールセン，キルステン
Original Assignee
ダコ デンマーク アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダコ デンマーク アクティーゼルスカブ filed Critical ダコ デンマーク アクティーゼルスカブ
Publication of JP2011520456A publication Critical patent/JP2011520456A/ja
Publication of JP2011520456A5 publication Critical patent/JP2011520456A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011509855A 2008-05-20 2009-05-20 抗癌療法に対する応答を予測するための組み合わせ方法 Pending JP2011520456A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200800696 2008-05-20
DKPA200800696 2008-05-20
US5494408P 2008-05-21 2008-05-21
US61/054,944 2008-05-21
PCT/DK2009/050116 WO2009140973A1 (en) 2008-05-20 2009-05-20 A combined method for predicting the response to an anti-cancer therapy

Publications (2)

Publication Number Publication Date
JP2011520456A true JP2011520456A (ja) 2011-07-21
JP2011520456A5 JP2011520456A5 (https=) 2012-07-05

Family

ID=40010544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509855A Pending JP2011520456A (ja) 2008-05-20 2009-05-20 抗癌療法に対する応答を予測するための組み合わせ方法

Country Status (7)

Country Link
US (1) US20110144047A1 (https=)
EP (1) EP2288729A1 (https=)
JP (1) JP2011520456A (https=)
CN (1) CN102099493A (https=)
AU (1) AU2009250169A1 (https=)
CA (1) CA2725171A1 (https=)
WO (1) WO2009140973A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6841609B2 (ja) 2015-07-10 2021-03-10 ３スキャン インコーポレイテッド 組織学的染色の空間的多重化
CN105524990A (zh) * 2015-12-30 2016-04-27 广州安必平医药科技股份有限公司 Her-2基因和/或top2a基因检测探针及其制备方法和试剂盒
CN105483255A (zh) * 2015-12-30 2016-04-13 广州安必平医药科技股份有限公司 Top2a基因检测探针及其制备方法和试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112746A1 (en) * 2006-04-01 2007-10-11 Dako Denmark A/S Method for performing prognoses for high-risk breast cancer patients using top2a gene aberrations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007112746A1 (en) * 2006-04-01 2007-10-11 Dako Denmark A/S Method for performing prognoses for high-risk breast cancer patients using top2a gene aberrations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014004624; Ｃｌｉｎｉｃａｌ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．１２，Ｎｏ．２３, 2006, ｐ．７０５４-７０５８ *
JPN6014004627; Ｔｈｅ　Ｏｎｃｏｌｏｇｉｓｔ Ｖｏｌ．１２, 2007, ｐ．３９７-４０５ *
JPN6014004631; Ｊｏｕｒｎａｌ　ｏｆ　Ｚｈｅｊｉａｎｇ　Ｕｎｉｖｅｒｓｉｔｙ　Ｓｃｉｅｎｃｅ Ｖｏｌ．４，Ｎｏ．４, 2003, ｐ．４９１-５０１ *

Also Published As

Publication number Publication date
CA2725171A1 (en) 2009-11-26
US20110144047A1 (en) 2011-06-16
CN102099493A (zh) 2011-06-15
AU2009250169A1 (en) 2009-11-26
EP2288729A1 (en) 2011-03-02
WO2009140973A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
Ding et al. Prognostic biomarkers of cutaneous melanoma
RU2739942C2 (ru) Терапевтические, диагностические и прогностические способы для рака мочевого пузыря
Ting et al. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma
CN102625849B (zh) 侦测致死细胞的方法与材料及其应用
AU2019339508B2 (en) Method of selection for treatment of subjects at risk of invasive breast cancer
EP3227687A1 (en) Dcis recurrence and invasive breast cancer
JP4759612B2 (ja) 癌治療化合物のｉｎ ｖｉｔｒｏにおける同定方法
JP2011520456A (ja) 抗癌療法に対する応答を予測するための組み合わせ方法
WO2016181979A1 (ja) Ｓｙｔ７・ｍｆｓｄ４・ｅｔｎｋ２発現量による胃癌肝転移の検査方法、検査キット、分子標的治療薬スクリーニング方法、医薬組成物
EP2574929A1 (en) Marker in diagnosing prostate cancer (PC)
Mountzios et al. Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab
Lotfy et al. Biochemical study of E-cadherin and SATB1 in urothelial bladder carcinoma of Egyptian patients
EP2732287B1 (en) Methods of prognosing chronic lymphocytic leukemia
TWI391660B (zh) 偵測致死細胞的方法與材料及其應用
KR101188693B1 (ko) 피부 편평세포암 진단 또는 예후 마커인 ＰｒｘⅠ 및 이의 용도
KR101179651B1 (ko) 피부 편평세포암 진단 또는 예후 마커인 ｎｑｏ-1 및 이의 용도
BR112017012553B1 (pt) Método de tratamento de um paciente que sofre de um câncer, método para o diagnóstico de um câncer, método para o prognóstico de um paciente que sofre de câncer, método para determinar se um paciente com um câncer e método para otimizar a eficácia terapêutica de uma terapia anticâncer
KR20110115039A (ko) 피부 편평세포암 진단 또는 예후 마커인 ＧＳＴｐｉ 및 이의 용도
WO2010084998A1 (en) A method of predicting the efficacy of a drug

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120612

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140410

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141021